Cargando…

P1204: TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY

Detalles Bibliográficos
Autores principales:	Lunning, M., Che, M., Gu, T., Le, T. K., Liu, F. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429103/ http://dx.doi.org/10.1097/01.HS9.0000847680.18950.05

Ejemplares similares

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
por: Verburg-Baltussen, E. J., et al.
Publicado: (2022)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

1204. The Effect of Coinfection with Babesiosis and Lyme Disease on Novel Biomarkers
por: Lum, Michael D, et al.
Publicado: (2020)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

OA12.04. The role of mind-body awareness in complementary and alternative medicine (CAM) outcomes
por: Sirois, F, et al.
Publicado: (2012)

1204. Increased Risk of Respiratory Infections Among Healthcare Personnel (HCP) Caring for Children
por: Nyquist, Ann-Christine, et al.
Publicado: (2019)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

1204. Evaluation Of An Antimicrobial Stewardship Scorecard For Hospitalized Patients With Community-Acquired Pneumonia
por: Klatt, Megan, et al.
Publicado: (2023)

P1204: AXICABTAGENE CILOLEUCEL VEIN-TO-VEIN TIME IN TRIAL OR REAL-WORLD SETTINGS VS OTHER CAR T-CELL THERAPIES FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
por: Locke, Frederick, et al.
Publicado: (2023)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.
por: Dodero, A., et al.
Publicado: (2022)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

(1204) Increased Antibody Response to a Five-Dose Regime of Covid-19 Vaccine in Lung Transplant Patients
por: van Gemert, J.P., et al.
Publicado: (2023)

Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204
por: Hwang, Jessica P., et al.
Publicado: (2022)

Addressing the Challenges of Aggressive Lymphomas
por: Byar, Katherine L., et al.
Publicado: (2020)

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
por: Matsumoto, Ryuji, et al.
Publicado: (2018)

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
por: Gómez-Ulloa, David, et al.
Publicado: (2020)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

1204. Assessing Perceptions and Efficacy of COVID-19 Case and Contact Investigations – Dallas County, Texas, 2020
por: Serrano, Jose, et al.
Publicado: (2021)

Erratum to “A large unruptured ectopic pregnancy” [Radiology Case Reports 16 (2021) 1204–1206]
por: Haddaden, Metri, et al.
Publicado: (2023)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
por: Abramson, Jeremy S., et al.
Publicado: (2023)

Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas
por: Lunning, M A, et al.
Publicado: (2015)

P1182: REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WHO RECEIVED CAR-T THERAPY
por: Liao, L., et al.
Publicado: (2022)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population
por: Wallia, Amisha, et al.
Publicado: (2021)

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
por: Davies, Jessica, et al.
Publicado: (2017)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
por: Park, Changhee, et al.
Publicado: (2021)

1204. The MDR Upon Admission Score for Shortening Time to Initiation of Appropriate Antimicrobial Therapy in the Era of Widespread Resistance to Antimicrobials
por: Chedid, Khalil, et al.
Publicado: (2018)

Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies
por: Gomez-Inhiesto, Elisa, et al.
Publicado: (2020)

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
por: Hutchings, Martin, et al.
Publicado: (2023)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Second-line treatment for primary central nervous system lymphoma
por: Reni, M, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_7s5osas4jj7c9kbkt75pstjvl3